[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Passioura, 2005 - Google Patents

Identification of genes with N-ras modulatory function in haematopoietic cells

Passioura, 2005

View PDF
Document ID
8656280535818169800
Author
Passioura T
Publication year

External Links

Snippet

Identification of genes with N-ras modulatory function in haematopoietic cells Page 1 Identification of genes with N-ras modulatory function in haematopoietic cells Author: Passioura, Toby Publication Date: 2005 DOI: https://doi.org/10.26190/unsworks/6424 License …
Continue reading at unsworks.unsw.edu.au (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Xie et al. Chronic myelogenous leukemia–initiating cells require Polycomb group protein EZH2
Ren Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia
Scholl et al. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis
Gekas et al. β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1
Chen et al. Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
Kim et al. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
Quéré et al. Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation
Lacombe et al. Genetic interaction between Kit and Scl
Lynn et al. C-jun overexpressing CAR-T cells are exhaustion-resistant and mediate enhanced antitumor activity
Nakamura et al. NF-κB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression
Passioura Identification of genes with N-ras modulatory function in haematopoietic cells
Clesham Targeting c-MYB in Acute Myeloid Leukaemia
Belenki Transcriptional control of cellular plasticity in cancer cell senescence
Tonc Uncovering a MYC-Driven Tumor-Suppressive Program in Proliferating Lymphocytes
Gu The GAB2/SHP2 Pathway in BCR-ABL1-Induced Hematopoietic Neoplasia
Santillan Functional specificity of the CBP domains in MLL-CBP induced immortalization
Dimitri et al. TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function
Piqué Borràs Molecular mechanisms of acute erythroid leukemia: learning from rare chromosomal translocations in pediatric patients
Caeser Elucidating oncogenic mechanisms in human B cell malignancies
Hasan JAK2V617F-positive Myeloproliferative Neoplasms: KI mouse models, interferon-α therapy and clonal architecture
Baumeister Dissecting the role of hypoxia-inducible factor 1 (HIF-1) in JAK2V617F-positive myeloproliferative neoplasms (MPN)
Kirkpatrick The Role of ETV6 Germline Mutations in B Cell Development and Predisposition to Leukemia
Jenkins Mechanisms of acute leukemia disease initiation and maintenance through manipulation of IGF1R and RUNX family members.
WRENCH Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukemia
Sufit Novel Approaches in the Treatment for Glioblastoma Multiforme